Critical challenges are facing biopharma in securing deals or preparing for self-commercialization. While biotechs are developing many complex and innovative new platforms, our research shows that large pharma companies are increasingly only willing to invest in commercially proven solutions. As a result, the number of sellers has increased significantly, but the number of buyers has remained relatively constant.

In this article, we analyze these challenges and offer recommendations on how biotechs can better prepare for commercialization readiness, even if they aim to seek partnerships.

Read the article